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— William Faulkner, Requiem for a Nun (1)SEE PAGE 27B ivalirudin, a direct thrombin inhibitor, isindicated as monotherapy in patients withunstable angina undergoing percutaneous
transluminal coronary angioplasty (PTCA) (2). Bivalir-
udin with provisional use of a glycoprotein IIb/IIIa in-
hibitor (GPI) is indicated as an anticoagulant in
patients undergoing percutaneous coronary interven-
tion (PCI) (2). Although not speciﬁcally approved for
patients with ST-segment elevation myocardial
infarction (STEMI) undergoing primary PCI (PPCI), it
is widely used to reduce periprocedural ischemic
complications. Until recently, bivalirudin monother-
apy was endorsed by the guidelines as a Class I, Level
of Evidence (LOE): B recommendation, and supported
in preference to unfractionated heparin (UFH) and a
GPI (Class IIa, LOE: B) in patients at high risk of
bleeding (3). These recommendations were primarily
driven by results of the landmark HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial, conduct-
ed nearly a decade ago (4). Clinical practice has since
evolved, mainly characterized by less frequent GPI
use, more frequent use of new and potent P2Y12 in-
hibitors, more frequent radial-artery PCI access,
and, in some regions, pre-hospital initiation ofrials published in JACC reﬂect the views of the authors and do not
sarily represent the views of JACC or the American College of
logy.
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atelet inhibitor.treatment (5). Accordingly, 4 additional trials evalu-
ated bivalirudin’s role in PPCI (5–8), yielding mixed
results and igniting a ﬁrestorm of controversy
regarding the optimal anticoagulant to support PPCI.In this issue of the Journal, Stone et al. (9) present
the 30-day pooled results of 2 multicenter, prospec-
tive, open-label randomized, controlled trials of biva-
lirudin during PPCI, HORIZONS-AMI and EUROMAX
(European Ambulance Acute Coronary Syndrome
[ACS] Angiography Trial). The authors conclude that
“despite evolution in PCI practice, technique and
adjunct pharmacology, anticoagulation during PPCI
with bivalirudin compared to heparin  GPI reduces
the 30-day rates of cardiac mortality, major and minor
bleeding, thrombocytopenia, and transfusions, at the
cost of an increase in acute stent thrombosis. These
results support use of bivalirudin for anticoagulation
of STEMI patients undergoing PPCI, independent of
vascular access site, choice of P2Y12 inhibitor, and
timing of drug initiation and discontinuation” (9). Are
these conclusions justiﬁed? To address this question,
several key issues merit consideration.
First, a particular strength of this report is the
availability of patient-level data for each study. From a
regulatory perspective, patient-level data permit
evaluation of each study’s quality and eligibility for
inclusion in a meta-analysis, allowing conﬁrmation of
study outcomes, particularly time-to-event outcomes,
and facilitating evaluation of the consistency of treat-
ment effects across important subgroups. The
LOE from a meta-analysis based solely on study-
level summary data, either prospective or retrospec-
tive, is generally considered lower (10). Other
essential dimensions of evidence derived from ameta-
analysis relevant for regulatory decision making are
TABLE Hierarchy of Evidence for Meta-analysis or Pooled Analysis*
Evidentiary Standard
Pooled analysis of
HORIZONS-AMI and EUROMAX
Prospectively planned (pre-speciﬁcation
minimizes potential for bias)
No (pre-speciﬁed in the EUROMAX protocol,
but results of HORIZONS-AMI known in
advance)
Lack of heterogeneity to justify pooling Statistical: yes
Clinical: no (substantial clinical heterogeneity
between the trials)
Exclusion of hypothesis-generating study No
Patient-level data (allows for time to event
analysis and robust inferences)
Yes
Multiplicity adjustment (allows for protection
against inﬂation of Type I error)
No (the likelihood of a ‘false-positive’
error not ruled out for 30-day cardiac
mortality)
Strength of evidence
 Statistically persuasive p value
(<0.001)
 Probability that meta-analytic
ﬁnding is due to chance
 Rigorous assessment of other
plausible explanations
 Weak evidence against the null for
cardiac mortality (p ¼ 0.03) and stent
thrombosis (0.04).Statistically
persuasive evidence for hemorrhagic
and hematologic endpoints favoring
bivalirudin (p < 0.001)
 Probability that reduced pooled
cardiac mortality is due to chance
not ruled out
 Rigorous assessment of other plausible
explanations not apparent
Biological and clinical plausibility
of the ﬁndings
No plausible explanation for reduced
cardiac mortality discernible
*Adapted from reference #10.
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40summarized in Table 1, which is adapted from the
White Paper which came out of the Public Meeting on
Meta-Analyses of Randomized Controlled Clinical
Trials for the Evaluation of Risk to Support Regulatory
Decisions (10). The investigators state that the EURO-
MAX protocol pre-speciﬁed the pooled analysis.
However, HORIZONS-AMI results were known, so it is
not strictly a prospective pooled analysis needed to
minimize potential bias (10). The authors justify
pooling due to a lack of statistical heterogeneity, a
necessary but not sufﬁcient criterion for pooling. One
could argue that given the substantial clinical hetero-
geneity across trials, which the investigators appro-
priately and carefully detail in Table 1 of their report,
they are not poolable. Furthermore, it is not clear what
new or unique insights are offered by the pooled re-
sults that cannot be inferred a priori from the individ-
ual trial results. The clearest ﬁndings from the 2 trials
are that bivalirudin increases the risk of acute stent
thrombosis while reducing bleeding complications.
Because the EUROMAX study did not show a
reduction, it is much less certain whether there is a
true mortality reduction with bivalirudin. Similarly,
EUROMAX did not replicate the reduction in Throm-
bolysis In Myocardial Infarction (TIMI) major bleeding
(prognostically more important, but less frequent
than protocol-deﬁned major bleeding) observed inHORIZONS-AMI, presumably due to EUROMAX’s lack
of pre-randomization heparin therapy and increased
use of radial access (5). Thus, although EUROMAX
failed to provide the conﬁrmatory evidence required to
support a regulatory claim (11), pooling results can
yield misleading inferences of consistent treatment
effects (reduction in cardiac mortality and TIMI major
bleeding) across the 2 trials.
Second, unconventional use of a composite efﬁ-
cacy (ischemic) and safety (bleeding) outcome, net
adverse cardiac events (NACE), biased the results of
both trials in favor of bivalirudin. Although com-
bining efﬁcacy and safety into a composite outcome
might be desirable to inﬂate the event rate and
enhance trial feasibility, it is often misleading
because relatively ineffective, but safer drugs can
appear as good as or better than effective drugs, as in
the unsubstantiated claims of bivalirudin’s superior-
ity over heparin (2). This was previously illustrated in
the REPLACE-2 (Randomized Evaluation of PCI
Linking Angiomax to Reduced Clinical Events 2) (12)
and ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) (13) trials, where the
difference in major bleeding events (risk reduction of
43% and 47%, respectively, in favor of bivalirudin)
exceeded the difference in MIs (13% and 9% respec-
tive risk increases), resulting in the NACE quadruple
composite endpoint favoring bivalirudin. Accord-
ingly, the U.S. Food and Drug Administration, in
direct challenge to the investigators’ interpretation,
did not allow a claim of statistical noninferiority for
the triple ischemic endpoint (2). Also, both ACUITY
and HORIZONS-AMI were confounded by asymmet-
rical GPI use (routine, selective, or bailout), and pre-
randomization heparin therapy (63% to 64% in the
former study and 65.6% in the latter study). Heparin
pretreatment could have contributed to the anti-
coagulation effect in the bivalirudin treatment arms,
making efﬁcacy attributable solely to bivalirudin
difﬁcult to determine. For example, in 615 patients in
HORIZONS-AMI in whom bivalirudin was not pre-
ceded by heparin pretreatment, the risk of major
adverse cardiac events numerically increased (rela-
tive risk: 1.39; 95% conﬁdence interval [CI]: 0.85 to
2.28) compared with a numerical decrease in those
receiving pretreatment heparin (relative risk: 0.81;
95% CI: 0.58 to 1.14; p for interaction ¼ 0.08) (4).
Similarly, asymmetrical GPI use could have contrib-
uted to the increased bleeding risk in the heparin
treatment arms, biasing the results to favor
bivalirudin.
Third, a major source of controversy is the choice
of comparator in the bivalirudin trials. It has been
argued that heparin monotherapy is inappropriate
J A C C V O L . 6 5 , N O . 1 , 2 0 1 5 Kaul
J A N U A R Y 6 / 1 3 , 2 0 1 5 : 3 9 – 4 2 Optimal Anticoagulant in Primary PCI
41for STEMI on the basis of pooled analysis of 8 ran-
domized trials demonstrating reduced death and
reinfarction by the addition of abciximab to heparin
during PPCI (14). Thus, randomizing patients to the
heparin monotherapy arm would have been “unethi-
cal.” Although ethical justiﬁcations to exclude treat-
ment choices should ideally be based on unequivocal
evidence of harm, this was clearly not the case, as GPI
use during PPCI was not strongly endorsed by the
2004 STEMI guidelines that preceded HORIZONS-AMI
enrollment (15). The Guidelines Writing Committee
believed that starting treatment with abciximab as
early as possible in patients undergoing PPCI was
reasonable, but, given the size and limitations of the
available dataset, assigned a Class IIa, LOE: B recom-
mendation. Data on tiroﬁban and eptiﬁbatide in PPCI
were far more limited than for abciximab, resulting in
a lower grade recommendation (Class IIb, LOE: B) (15).
A strong argument for heparin monotherapy could be
indirectly derived from the results of the ACUITY trial.
The addition of GPI to bivalirudin did not provide any
incremental ischemic beneﬁt, but nulliﬁed the
bleeding advantage of bivalirudin monotherapy (13).
The choice of heparin monotherapy (with bailout GPI)
was recently vindicated in the HEAT-PPCI (How
Effective Are Antithrombotic Therapies in Primary
Percutaneous Coronary Intervention) trial, which
demonstrated reduced risk of thrombotic complica-
tions without increased bleeding risk compared with
bivalirudin therapy (6). HEAT-PPCI has been heavily
scrutinized and criticized, with questions raised
against its ethics, the reliability of single-center trial
results, the reduced duration of post-procedure
bivalirudin therapy to offset the risk of acute stent
thrombosis, and the inadequate degree of anti-
coagulation achieved with bivalirudin. The study in-
vestigators and editorialists offered reasonable and
convincing rebuttals (16,17), prompting the most
recent guidelines to downgrade the bivalirudin
recommendation to Class IIa, LOE: A while retaining
treatment with UFH as a Class I, LOE: C recommen-
dation (18). Questions persist, especially in light of
the recently reported conﬁrmation of the results of
the earlier 2 trials by the unpublished BRIGHT
(Bivalirudin Versus Heparin Monotherapy and Glyco-
protein IIb/IIIa Plus Heparin for Patients With AMI
Undergoing Coronary Stenting) trial (8). Finally, in the
BRAVE-4 (Bavarian Reperfusion Alternatives Evalua-
tion -4) trial, neither the composite of ischemic com-
plications nor bleeding was favorably affected by
prasugrel plus bivalirudin compared with clopidogrel
plus UFH (7). However, in view of premature termi-
nation of BRAVE-4 due to slow recruitment, the re-
sults must be interpreted with caution.Fourth, much has been made of the observed
reduction in cardiac mortality in favor of bivalirudin
in the HORIZONS-AMI trial, with some arguing this
ﬁnding alone as the raison d’être for using bivalirudin
during PPCI. Bivalirudin treatment resulted in a sig-
niﬁcant reduction in cardiac mortality, present by
30 days (1.8% vs. 2.9%, hazard ratio [HR]: 0.62, 95%
CI: 0.40 to 0.95; p ¼ 0.03) (4) and increasing over
3 years (2.9% vs. 5.1%; HR: 0.56, 95% CI: 0.40 to 0.80;
p ¼ 0.001) (19). However, its reliability is question-
able; it was not a pre-speciﬁed endpoint and there-
fore not adequately powered for comparison. The
p value was marginal with a wide CI. The strength of
evidence is often summarized using a Bayes factor, a
measure of how well 2 competing hypotheses (the
null and the alternate) predict the data (20). The
p value of 0.03 for cardiac mortality translates into a
minimal Bayes factor of 0.088, meaning the evidence
supports the null hypothesis approximately one-
eleventh as strongly as the alternative, reducing the
null probability from 50% pretrial to 8% post-trial,
and a more skeptical, albeit plausible, null probabil-
ity of 75% pre-trial to 21% post-trial, not strong evi-
dence against the null. The p value was not adjusted
for multiple comparisons, inﬂating the possibility
of type I error for the 30-day endpoint (less likely
for the 3-year endpoint given the statistically
persuasive p ¼ 0.001). The precise mechanisms link-
ing bivalirudin to mortality reduction have not been
elucidated and were not accounted for by the pre-
vention of bleeding, thrombocytopenia, or reinfarc-
tion (all reduced at 3 years) (21).
Furthermore, 2 mechanisms by which bivali-
rudin could potentially yield a mortality beneﬁt,
biomarker-determined or magnetic resonance imag-
ing–determined infarct size or left ventricular
ejection fraction, were no different (21). Lack of rep-
lication in other studies (5,6,13) further challenges the
reliability of the HORIZONS-AMI mortality ﬁndings.
The play of chance cannot be eliminated on the basis
of the totality of the evidence (lack of pre-
speciﬁcation, replication, and control of type I error,
all of which are required to support regulatory
claims). Given the seriousness of the outcome, some
have argued that the mortality reduction cannot be
ignored. Probabilistic estimates are insensitive to the
seriousness of outcome events, especially if unex-
pected; the unexpected mortality beneﬁt observed in
HORIZONS-AMI is as likely as any nonfatal, nonse-
rious outcome to be due to chance. A registration
trial supporting mortality reduction would require
tens of thousands of patients enrolled in a prospec-
tive, well-designed, adequately controlled and pow-
ered trial. Thus, the signiﬁcant reduction in cardiac
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reliable. Accordingly, its use as an argument to inform
guideline recommendations and guide clinical prac-
tice is unwarranted.
Where do we go from here? Although the evi-
dentiary landscape in support of antithrombotic
treatment choices during PPCI has been enriched
by the bivalirudin trials, recent data question the
role of bivalirudin. It costs nearly 400-fold more
than heparin, with no discernible efﬁcacy or sub-
stantial safety advantage. Some have appropriately
recalibrated their opinions and changed practice
in alignment with the evidence, whereas othersdoggedly maintain the status quo. Arguably, a
new, carefully designed trial is required to cut the
Gordian knot and adjudicate the uncertainties.
Until then, like ﬁne wine that never goes out of
fashion, it is time for out with the new (bivalir-
udin), in with the old (heparin monotherapy with
bailout GPI).
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